"Continued operations are dependent on our ability to complete other equity or debt funding transactions. Such capital formation activities may not be available or may not be available on reasonable terms. If we do not obtain additional equity or debt funding in the near future, our cash resources will rapidly be depleted and we will be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained."
Daaaaahhhh. That is how 99.9% of all new pharma companies operate. Quarter to Quarter with funding, but they do have a pipeline with tremendous potential, that is how they raise money. Of course we don't know the conditions from time to time, but we are talking a market cap of under $100 Million in an industry that speaks in the billions with potential of any one product. THIS is how the big pharma companies get their pipeline by cherry picking the small ones as they reach goals that meet their pipeline needs and doing a Stock Exchange cost them next to NOTHING to acquire the next big deal.